A rapid and sensitive real-time PCR assay for the K65R drug resistance mutation in SIV reverse transcriptase

AIDS Research and Human Retroviruses

Volumn 22, Issue 9, 2006, Pages 912-916

  Johnson, Jeffrey A ^a,d   Van Rompay, Koen K A ^b   Delwart, Eric ^c   Heneine, Walid ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACACA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE;

ADENINE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; MACACA; MICROBIAL SENSITIVITY TESTS; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SENSITIVITY AND SPECIFICITY; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33751027170     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.912     Document Type: Article

References (16)

1. Ambrose Z, Boltz V, Palmer S, Coffin JM, Hughes, SH, and Kewalramani VN: In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol 2004;78:13553-13561.
2. North TW, Van Rompay KK, Higgins J, et al.: Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol 2005;79:7349-7354.
3. Van Rompay KK: Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments. AIDS Rev 2005;7:67-83.
4. Tsai CC, Follis KE, Sabo A, et al.: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995;270:1121-1122.
5. Van Rompay KK, Cherrington JM, Marthas ML et al.: 9-[2-(Phosphonomethoxy) propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother 1996;40:2586-2591.
6. Tsai CC, Emau P, Sun JC, et al.: Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection. J Med Primatol 2000;29:248-258.
7. Smith MS, Foresman L, Lopez GJ, et al.: Lasting effects of transient postinoculation tenofovir 19-R-(2-phosphonomethoxypropyl)adenine] treatment on SH1V(KU2) infection of rhesus macaques. Virology 2000;277:306-315.
8. Van Rompay KK, Singh RP, Pahar B, et al.: CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J Virol 2004;78:5324-5337.
9. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, and Heneine W.: Susceptibility of HIV-2, S1V and SH1V to various anti-HIV-1 compounds: implications for treatment and post-exposure prophylaxis. Antivir Ther 2004;9:57-65.
10. Subbarao S, Otten R, Ramos A, et al.: Chemoprophylaxis with oral tenofovir disoproxil fumarate delays but does not prevent infection in Rhesus macaques given repeated rectal challenges of SH1V. 12th Conference on retroviruses and Opportunistic Infections, February 22-25, 2005, Boston MA, Abstract #136LB.
11. Wainberg MA, Miller MD, Quan Y, et al.: In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999;4:87-94.
12. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, and Miller MD: Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients trealed with tenofovir DF. AIDS. 2002;16:1227-1235.
13. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, and Naeger LK: Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002;46:3437-3446.
14. Johnson JA, Li JF, Morris L, et al.: Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005;192:16-23.
15. Van Rompay KK, Cherrington JM, Marthas ML, et al.: 9-[2- (Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrob Agents Chemother 1999;43:802-812.
16. Magierowska M, Bernardin F, Garg S, et al.: Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques. J Virol 2004;78:2434-2444.